Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
$TBPH
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
97
ISIN
KYG8807B1068
Website
TBPH Metrics
BasicAdvanced
$565M
-
-$1.19
-0.10
-
Price and volume
Market cap
$565M
Beta
-0.1
52-week high
$11.82
52-week low
$7.44
Average daily volume
296K
Financial strength
Current ratio
4.77
Quick ratio
4.641
Long term debt to equity
22.502
Total debt to equity
22.502
Interest coverage (TTM)
-17.84%
Profitability
EBITDA (TTM)
-43.604
Gross margin (TTM)
42.93%
Net profit margin (TTM)
-89.38%
Operating margin (TTM)
-69.96%
Effective tax rate (TTM)
-20.65%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
-7.98%
Return on equity (TTM)
-31.46%
Valuation
Price to revenue (TTM)
8.519
Price to book
3.4
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
17.221
Free cash flow yield (TTM)
5.81%
Free cash flow per share (TTM)
65.62%
Growth
Revenue change (TTM)
6.11%
Earnings per share change (TTM)
36.75%
3-year revenue growth (CAGR)
6.36%
10-year revenue growth (CAGR)
7.68%
3-year earnings per share growth (CAGR)
-16.32%
10-year earnings per share growth (CAGR)
-16.09%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
Bulls say / Bears say
Theravance Biopharma achieved record YUPELRI® (revefenacin) net sales of $66.7 million in Q4 2024, marking a 10% year-over-year increase, indicating strong market demand and effective commercialization strategies. (Theravance Biopharma News Release)
The company received a $50 million milestone payment from GSK due to TRELEGY's net sales reaching $3.46 billion in 2024, reflecting the product's robust performance and contributing significantly to Theravance's revenue stream. (Theravance Biopharma News Release)
Theravance's strategic sale of its remaining royalty interest in TRELEGY to GSK for $225 million in June 2025 has bolstered its cash reserves, providing financial flexibility for future investments and shareholder returns. (Theravance Biopharma News Release)
Theravance reported a GAAP net loss of $13.6 million in Q1 2025, an increase from the $11.7 million loss in Q1 2024, indicating ongoing financial challenges despite revenue growth. (Theravance Biopharma News Release)
The company's ampreloxetine program faced delays, with final patient enrollment in the CYPRESS study pushed to mid-2025, potentially postponing revenue generation from this pipeline candidate. (Theravance Biopharma News Release)
Theravance underwent a 17% workforce reduction in February 2023, reflecting operational challenges and potential impacts on future research and development capabilities. (BioPharma Dive)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $565M as of July 15, 2025.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of July 15, 2025.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of -0.1. This means that it has an inverse relation to market volatility.